ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bachem has signed an agreement to supply large volumes of peptides to an undisclosed customer. Manufacturing will primarily take place at the company’s large-scale production facility currently under construction in Bubendorf, Switzerland. The Swiss firm says the order commits it to supplying a volume of peptides valued at over $530 million between 2027 and 2031. The facility at Budendorf, scheduled to open in 2024, will nearly double its manufacturing capacity for peptides and oligonucleotides.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter